Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.33
MCK's Cash-to-Debt is ranked lower than
66% of the 56 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.60 vs. MCK: 0.33 )
Ranked among companies with meaningful Cash-to-Debt only.
MCK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.5 Max: 2.16
Current: 0.33
0.03
2.16
Equity-to-Asset 0.18
MCK's Equity-to-Asset is ranked lower than
89% of the 55 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.41 vs. MCK: 0.18 )
Ranked among companies with meaningful Equity-to-Asset only.
MCK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.15  Med: 0.26 Max: 0.34
Current: 0.18
0.15
0.34
Interest Coverage 23.08
MCK's Interest Coverage is ranked higher than
63% of the 46 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.51 vs. MCK: 23.08 )
Ranked among companies with meaningful Interest Coverage only.
MCK' s Interest Coverage Range Over the Past 10 Years
Min: 7.81  Med: 9.11 Max: 23.08
Current: 23.08
7.81
23.08
Piotroski F-Score: 4
Altman Z-Score: 4.40
Beneish M-Score: -2.24
WACC vs ROIC
8.32%
38.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 3.58
MCK's Operating Margin % is ranked lower than
55% of the 56 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.80 vs. MCK: 3.58 )
Ranked among companies with meaningful Operating Margin % only.
MCK' s Operating Margin % Range Over the Past 10 Years
Min: 1.12  Med: 1.74 Max: 3.58
Current: 3.58
1.12
3.58
Net Margin % 2.55
MCK's Net Margin % is ranked higher than
52% of the 56 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.80 vs. MCK: 2.55 )
Ranked among companies with meaningful Net Margin % only.
MCK' s Net Margin % Range Over the Past 10 Years
Min: 0.77  Med: 1.08 Max: 2.55
Current: 2.55
0.77
2.55
ROE % 54.62
MCK's ROE % is ranked higher than
98% of the 55 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.49 vs. MCK: 54.62 )
Ranked among companies with meaningful ROE % only.
MCK' s ROE % Range Over the Past 10 Years
Min: 13.37  Med: 18.14 Max: 54.62
Current: 54.62
13.37
54.62
ROA % 8.69
MCK's ROA % is ranked higher than
93% of the 56 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.76 vs. MCK: 8.69 )
Ranked among companies with meaningful ROA % only.
MCK' s ROA % Range Over the Past 10 Years
Min: 2.79  Med: 4.08 Max: 8.69
Current: 8.69
2.79
8.69
ROC (Joel Greenblatt) % 232.96
MCK's ROC (Joel Greenblatt) % is ranked higher than
95% of the 55 Companies
in the Global Medical Distribution industry.

( Industry Median: 23.31 vs. MCK: 232.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MCK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 63.18  Med: 122.7 Max: 261.45
Current: 232.96
63.18
261.45
3-Year Revenue Growth Rate 14.70
MCK's 3-Year Revenue Growth Rate is ranked higher than
67% of the 45 Companies
in the Global Medical Distribution industry.

( Industry Median: 9.00 vs. MCK: 14.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MCK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20  Med: 11.3 Max: 26.1
Current: 14.7
-20
26.1
3-Year EBITDA Growth Rate 39.80
MCK's 3-Year EBITDA Growth Rate is ranked higher than
90% of the 39 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.40 vs. MCK: 39.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MCK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.9  Med: 8.5 Max: 146.9
Current: 39.8
-47.9
146.9
3-Year EPS without NRI Growth Rate 56.40
MCK's 3-Year EPS without NRI Growth Rate is ranked higher than
92% of the 37 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.40 vs. MCK: 56.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MCK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.5  Med: 13.3 Max: 87.1
Current: 56.4
-44.5
87.1
GuruFocus has detected 1 Warning Sign with McKesson Corp $MCK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MCK's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

MCK Guru Trades in Q3 2016

Paul Tudor Jones 9,323 sh (New)
Eaton Vance Worldwide Health Sciences Fund 193,108 sh (New)
Jim Simons 758,300 sh (+678.54%)
Charles Brandes 55,134 sh (+40.34%)
Joel Greenblatt 235,225 sh (+29.69%)
Manning & Napier Advisors, Inc 45,250 sh (+24.66%)
Ray Dalio 41,359 sh (+23.98%)
John Paulson 67,000 sh (+10.74%)
Wallace Weitz 58,080 sh (+0.70%)
Vanguard Health Care Fund 7,165,280 sh (unchged)
Mario Gabelli 5,000 sh (unchged)
David Dreman 5,004 sh (unchged)
Tom Gayner 9,100 sh (unchged)
Jerome Dodson 40,000 sh (unchged)
Steven Cohen Sold Out
Scott Black 9,035 sh (-0.13%)
John Buckingham 22,140 sh (-0.57%)
Ronald Muhlenkamp 45,753 sh (-0.93%)
Arnold Van Den Berg 67,944 sh (-1.41%)
Diamond Hill Capital 1,360 sh (-1.59%)
First Pacific Advisors 83,080 sh (-2.60%)
» More
Q4 2016

MCK Guru Trades in Q4 2016

Seth Klarman 1,000,000 sh (New)
Richard Pzena 186,289 sh (New)
David Tepper 275,000 sh (New)
Larry Robbins 683,516 sh (New)
Steven Cohen 43,100 sh (New)
Jana Partners 386,868 sh (New)
Charles Brandes 1,045,486 sh (+1796.26%)
Diamond Hill Capital 21,280 sh (+1464.71%)
Jerome Dodson 119,000 sh (+197.50%)
Paul Tudor Jones 26,546 sh (+184.74%)
Ray Dalio 67,759 sh (+63.83%)
Ronald Muhlenkamp 71,767 sh (+56.86%)
Joel Greenblatt 277,057 sh (+17.78%)
Vanguard Health Care Fund 8,218,500 sh (+14.70%)
Mario Gabelli 5,000 sh (unchged)
Tom Gayner 9,100 sh (unchged)
Wallace Weitz Sold Out
John Paulson Sold Out
Jim Simons Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Scott Black 8,813 sh (-2.46%)
Arnold Van Den Berg 66,107 sh (-2.70%)
John Buckingham 21,226 sh (-4.13%)
Manning & Napier Advisors, Inc 38,800 sh (-14.25%)
David Dreman 3,925 sh (-21.56%)
First Pacific Advisors 57,200 sh (-31.15%)
» More
Q1 2017

MCK Guru Trades in Q1 2017

George Soros 1,400 sh (New)
Richard Pzena 2,077,104 sh (+1014.99%)
Steven Cohen 358,500 sh (+731.79%)
Scott Black 15,006 sh (+70.27%)
Jerome Dodson 168,000 sh (+41.18%)
Larry Robbins 917,776 sh (+34.27%)
Arnold Van Den Berg 80,140 sh (+21.23%)
Charles Brandes 1,121,845 sh (+7.30%)
John Buckingham 21,254 sh (+0.13%)
Mario Gabelli 5,000 sh (unchged)
David Dreman 3,925 sh (unchged)
Seth Klarman 1,000,000 sh (unchged)
Tom Gayner 9,100 sh (unchged)
Jana Partners Sold Out
Diamond Hill Capital 21,251 sh (-0.14%)
Ronald Muhlenkamp 71,430 sh (-0.47%)
Vanguard Health Care Fund 8,002,819 sh (-2.62%)
First Pacific Advisors 48,300 sh (-15.56%)
Ray Dalio 57,101 sh (-15.73%)
Manning & Napier Advisors, Inc 26,355 sh (-32.07%)
Paul Tudor Jones 15,721 sh (-40.78%)
Joel Greenblatt 129,666 sh (-53.20%)
David Tepper 100,000 sh (-63.64%)
» More
Q2 2017

MCK Guru Trades in Q2 2017

Jerome Dodson 168,000 sh (unchged)
Manning & Napier Advisors, Inc 21,370 sh (-18.91%)
» More
» Details

Insider Trades

Latest Guru Trades with MCK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Distribution » Medical Distribution    NAICS: 424210    SIC: 5122
Compare:NYSE:CAH, NYSE:ABC, NAS:HSIC, NAS:PDCO, NYSE:PBH, NYSE:OMI, NYSE:PMC, OTCPK:SNYR, OTCPK:FZMD » details
Traded in other countries:MCK.Germany, MCK.Mexico,
Headquarter Location:USA
McKesson Corp provides medicines, pharmaceutical supplies, information and care management products and services across the healthcare industry. It operates with two segments namely McKesson Distribution Solutions and McKesson Technology Solutions.

McKesson is a major distributor of pharmaceuticals, specialty drugs, and medical products in North America. The firm plays a critical role along the pharmaceutical supply chain as it is able to procure and distribute drugs more efficiently than its pharmacy client and pharma manufacturing suppliers.

Guru Investment Theses on McKesson Corp

Weitz Funds Comments on McKesson - Jan 26, 2017

McKesson (NYSE:MCK) distributes drugs, equipment and health and beauty care products throughout North America and portions of Europe. The company also delivers software solutions and outsourced services to hospitals, pharmacies and other healthcare organizations. Shares of McKesson declined in October as the company experienced unexpected competitive losses from its core independent pharmacy customer base. The source (price competition) and magnitude of these developments led to a downward revision in McKesson’s earnings power and undermined one of the pillars of our investment thesis – that drug wholesalers operate within a competitive, but otherwise rational, oligopoly. Our estimate of McKesson’s business value declined, and we elected to close our small position at a modest loss.



From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Mario Gabelli Comments on McKesson Corp - Jul 26, 2016

McKesson Corp. (NYSE:MCK) (0.1%) (MCK – $186.65 – NYSE) is one of the three largest drug wholesalers in the world and has been expanding aggressively outside the U.S. through the acquisition of Celesio and several other European companies. McKesson recently announced an innovative divestiture of its information technology businesses; it will merge it with privately owned Change Healthcare and the combined company will go public next year. In its core wholesaling business, the company has stabilized its performance after several contract losses, recently signing a large new contract with Walmart. McKesson retains a balanced capital return policy that invests first in its core business but then returns a significant amount of cash to shareholders via dividends and share repurchases, which has helped the company post superior long term growth and returns.

From Mario Gabelli (Trades, Portfolio)'s Gabelli Asset Fund second quarter 2016 commentary.

Check out Mario Gabelli latest stock trades

Mario Gabelli Comments on McKesson Corp - Jul 25, 2016

McKesson Corp. (NYSE:MCK) (0.1%) (MCK – $186.65 – NYSE) is one of the three largest drug wholesalers in the world and has been expanding aggressively outside the U.S. through the acquisition of Celesio and several other European companies. McKesson recently announced an innovative divestiture of its information technology businesses; it will merge it with privately owned Change Healthcare and the combined company will go public next year. In its core wholesaling business, the company has stabilized its performance after several contract losses, recently signing a large new contract with Walmart. McKesson retains a balanced capital return policy that invests first in its core business but then returns a significant amount of cash to shareholders via dividends and share repurchases, which has helped the company post superior long term growth and returns.



From the Gabelli ABC Merger Arbitrage Fund second quarter 2016 shareholder letter.



Check out Mario Gabelli latest stock trades

Parnassus Fund Comments on McKesson - May 09, 2016

McKesson (NYSE:MCK), the largest drug distributor in the nation, sliced 50 basis points from the Fund’s return, as the stock declined 20.3% from $197.23 to $157.25. The stock moved lower after management provided weaker-than-expected guidance due to weaker generic drug prices. McKesson also lost some drugstore customers, as several chains were acquired by firms using other distributors. Despite these headwinds, we expect revenue to recover through organic growth and attracting new customers. McKesson provides significant value to consumers by improving the efficiency of drug procurement and delivery, which we believe will generate shareholder value over the long term.



From the Parnassus Fund first quarter 2016 shareholder letter.



Check out Jerome Dodson latest stock trades

Wallace Weitz Comments on McKesson - Apr 22, 2016

McKesson (NYSE:MCK) distributes drugs, equipment, and health and beauty products throughout North America and portions of Europe. The company also delivers software solutions and outsourced services to hospitals, pharmacies and other healthcare organizations. Merger-related customer losses (McKesson accounts Omnicare, Target Pharmacy and Rite Aid are moving to competing wholesalers after being acquired), the return of generic drug deflation and concerns of lower future branded drug inflation combined to drive McKesson’s stock down nearly 40% from its high last summer. Having done detailed work on the company roughly nine years prior, we sharpened our pencils again late last year and initiated a position at $150 in January. The drug wholesaling business is an attractive oligopoly characterized by intense but rational competition, stable growth, healthy returns on capital and consistent excess cash generation. While McKesson’s business faces some near-term headwinds, we believe it is an attractive investment over the long term.

From Wallace Weitz (Trades, Portfolio)'s Weitz Value Fund 1st quarter 2016 commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about McKesson Corp

Insiders Roundup: SeaWorld, Kinder Morgan, Salesforce Largest insider trades for the week of May 29
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “June 2017” and “May 2017” and All Insider Sales to “$5,000,000+.” Read more...
Richard Pzena Invests in 3 Health Care Companies Guru releases 1st-quarter portfolio
Richard Pzena (Trades, Portfolio) gained 14 new holdings during the first quarter. Among them were three health care stocks, including Mylan NV(NASDAQ:MYL), Cardinal Health Inc. (NYSE:CAH) and Biogen Inc. (NASDAQ:BIIB). Read more...
What’s the Next Berkshire Hathaway Acquisition? With a growing cash pile, Buffett needs to bag another big target soon
With the Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B)  annual meeting convening this Saturday, many investors are wondering what and when the company's next big acquisition will be. Berkshire has around $75 billion in cash and the speculation has been that Warren Buffett (TradesPortfolio) is looking for companies with market values of $25 to $75 billion. I built a screen to find companies in that ballpark that also have economic moats, and then created a list of potential prospects. Read more...
The Threat and Risk of Rising Interest Rates: Separating Fact From Fiction Can the inverse relationship between stock valuations and interest rates be relied upon?
Introduction Read more...
Seth Klarman's Largest 4th-Quarter Buys Guru's largest trades include expanding 5 holdings, buying 2 others
Value investor Seth Klarman (Trades, Portfolio) is portfolio manager of The Baupost Group. During the fourth quarter, he bought shares in the following stocks: Read more...
Jerome Dodson Adds to 9 Positions in 4th Quarter Guru's purchases involve 4 health care-related companies
Parnassus Investments founder and President Jerome Dodson (Trades, Portfolio) made no new buys in the fourth quarter, but he added to nine existing positions in his portfolio. Read more...
Jana Partners' Largest 4th-Quarter Buys HD Supply Holdings, Bristol-Myers and Salesforce among top trades
Jana Partners (TradesPortfolio) is an investment manager specializing in event-driven investing. The firm was founded in 2001 by Barry Rosenstein. The firm manages approximately $11 billion in investments and commitments and is located in New York. During the fourth quarter, the firm invested in the following stocks. Read more...
Weitz Funds Comments on McKesson Guru stock highlight
McKesson (NYSE:MCK) distributes drugs, equipment and health and beauty care products throughout North America and portions of Europe. The company also delivers software solutions and outsourced services to hospitals, pharmacies and other healthcare organizations. Shares of McKesson declined in October as the company experienced unexpected competitive losses from its core independent pharmacy customer base. The source (price competition) and magnitude of these developments led to a downward revision in McKesson’s earnings power and undermined one of the pillars of our investment thesis – that drug wholesalers operate within a competitive, but otherwise rational, oligopoly. Our estimate of McKesson’s business value declined, and we elected to close our small position at a modest loss. Read more...
Samuel Isaly Makes 9 New Buys in 3rd Quarter 5 acquisitions have impacts greater than 2% on portfolio
Samuel Isaly (Trades, Portfolio) of Eaton Vance Worldwide Health Sciences Fund acquired nine new holdings in the third quarter ended Aug. 31. Five of the holdings had impacts greater than 2% on the portfolio. Read more...
12 Ways to Protect Yourself in Case the Company or Market Craters Be proactive about potential company or market collapses by using analytical tools, one of the stop variations or protective stock options
We do not know when our individual stocks, or even whole markets, will get whacked again. Nor do we know by how much. But we can be certain major reversals or corrections will happen sooner or later to many holdings. Read more...

Ratios

vs
industry
vs
history
PE Ratio 7.31
MCK's PE Ratio is ranked higher than
91% of the 45 Companies
in the Global Medical Distribution industry.

( Industry Median: 20.11 vs. MCK: 7.31 )
Ranked among companies with meaningful PE Ratio only.
MCK' s PE Ratio Range Over the Past 10 Years
Min: 5.98  Med: 17.84 Max: 38.44
Current: 7.31
5.98
38.44
Forward PE Ratio 13.79
MCK's Forward PE Ratio is ranked higher than
73% of the 15 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.51 vs. MCK: 13.79 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 7.13
MCK's PE Ratio without NRI is ranked higher than
91% of the 46 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.11 vs. MCK: 7.13 )
Ranked among companies with meaningful PE Ratio without NRI only.
MCK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.83  Med: 17.51 Max: 33.83
Current: 7.13
5.83
33.83
Price-to-Owner-Earnings 4.39
MCK's Price-to-Owner-Earnings is ranked higher than
91% of the 32 Companies
in the Global Medical Distribution industry.

( Industry Median: 27.03 vs. MCK: 4.39 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MCK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.59  Med: 12.31 Max: 37.98
Current: 4.39
3.59
37.98
PB Ratio 3.15
MCK's PB Ratio is ranked lower than
60% of the 55 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.38 vs. MCK: 3.15 )
Ranked among companies with meaningful PB Ratio only.
MCK' s PB Ratio Range Over the Past 10 Years
Min: 1.31  Med: 2.91 Max: 6.98
Current: 3.15
1.31
6.98
PS Ratio 0.19
MCK's PS Ratio is ranked higher than
89% of the 55 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.91 vs. MCK: 0.19 )
Ranked among companies with meaningful PS Ratio only.
MCK' s PS Ratio Range Over the Past 10 Years
Min: 0.08  Med: 0.18 Max: 0.32
Current: 0.19
0.08
0.32
Price-to-Free-Cash-Flow 8.88
MCK's Price-to-Free-Cash-Flow is ranked higher than
92% of the 24 Companies
in the Global Medical Distribution industry.

( Industry Median: 19.40 vs. MCK: 8.88 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MCK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.4  Med: 12.35 Max: 41.89
Current: 8.88
5.4
41.89
Price-to-Operating-Cash-Flow 7.81
MCK's Price-to-Operating-Cash-Flow is ranked higher than
82% of the 28 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.51 vs. MCK: 7.81 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MCK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.87  Med: 10.32 Max: 89.13
Current: 7.81
4.87
89.13
EV-to-EBIT 5.73
MCK's EV-to-EBIT is ranked higher than
93% of the 45 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.08 vs. MCK: 5.73 )
Ranked among companies with meaningful EV-to-EBIT only.
MCK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 11.3 Max: 22.5
Current: 5.73
4.9
22.5
EV-to-EBITDA 5.06
MCK's EV-to-EBITDA is ranked higher than
93% of the 46 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.22 vs. MCK: 5.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
MCK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 9.1 Max: 16.9
Current: 5.06
4.3
16.9
PEG Ratio 0.29
MCK's PEG Ratio is ranked higher than
97% of the 30 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.21 vs. MCK: 0.29 )
Ranked among companies with meaningful PEG Ratio only.
MCK' s PEG Ratio Range Over the Past 10 Years
Min: 0.17  Med: 1.2 Max: 7.26
Current: 0.29
0.17
7.26
Shiller PE Ratio 22.32
MCK's Shiller PE Ratio is ranked higher than
75% of the 20 Companies
in the Global Medical Distribution industry.

( Industry Median: 34.94 vs. MCK: 22.32 )
Ranked among companies with meaningful Shiller PE Ratio only.
MCK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.98  Med: 29.54 Max: 51.97
Current: 22.32
14.98
51.97
Current Ratio 1.04
MCK's Current Ratio is ranked lower than
89% of the 55 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.49 vs. MCK: 1.04 )
Ranked among companies with meaningful Current Ratio only.
MCK' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.26 Max: 1.59
Current: 1.04
1.04
1.59
Quick Ratio 0.61
MCK's Quick Ratio is ranked lower than
87% of the 55 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.07 vs. MCK: 0.61 )
Ranked among companies with meaningful Quick Ratio only.
MCK' s Quick Ratio Range Over the Past 10 Years
Min: 0.57  Med: 0.65 Max: 0.75
Current: 0.61
0.57
0.75
Days Inventory 30.21
MCK's Days Inventory is ranked higher than
63% of the 54 Companies
in the Global Medical Distribution industry.

( Industry Median: 39.39 vs. MCK: 30.21 )
Ranked among companies with meaningful Days Inventory only.
MCK' s Days Inventory Range Over the Past 10 Years
Min: 29.83  Med: 31.71 Max: 33.37
Current: 30.21
29.83
33.37
Days Sales Outstanding 26.85
MCK's Days Sales Outstanding is ranked higher than
85% of the 46 Companies
in the Global Medical Distribution industry.

( Industry Median: 61.58 vs. MCK: 26.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
MCK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.36  Med: 26.8 Max: 33.27
Current: 26.85
22.36
33.27
Days Payable 60.47
MCK's Days Payable is ranked lower than
59% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 69.74 vs. MCK: 60.47 )
Ranked among companies with meaningful Days Payable only.
MCK' s Days Payable Range Over the Past 10 Years
Min: 45.42  Med: 54.8 Max: 60.49
Current: 60.47
45.42
60.49

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.68
MCK's Dividend Yield % is ranked lower than
79% of the 63 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.42 vs. MCK: 0.68 )
Ranked among companies with meaningful Dividend Yield % only.
MCK' s Dividend Yield % Range Over the Past 10 Years
Min: 0.35  Med: 0.69 Max: 1.42
Current: 0.68
0.35
1.42
Dividend Payout Ratio 0.05
MCK's Dividend Payout Ratio is ranked higher than
92% of the 38 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.61 vs. MCK: 0.05 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MCK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.05  Med: 0.13 Max: 0.17
Current: 0.05
0.05
0.17
3-Year Dividend Growth Rate 6.80
MCK's 3-Year Dividend Growth Rate is ranked lower than
63% of the 27 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.00 vs. MCK: 6.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MCK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -21.7  Med: 0 Max: 44.2
Current: 6.8
-21.7
44.2
Forward Dividend Yield % 0.67
MCK's Forward Dividend Yield % is ranked lower than
83% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.54 vs. MCK: 0.67 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.98
MCK's 5-Year Yield-on-Cost % is ranked lower than
86% of the 72 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.05 vs. MCK: 0.98 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MCK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.51  Med: 1 Max: 2.07
Current: 0.98
0.51
2.07
3-Year Average Share Buyback Ratio 3.00
MCK's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 36 Companies
in the Global Medical Distribution industry.

( Industry Median: -2.30 vs. MCK: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MCK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -47  Med: -0.15 Max: 5.7
Current: 3
-47
5.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.70
MCK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
93% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.70 vs. MCK: 0.70 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MCK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.6  Med: 0.93 Max: 23.1
Current: 0.7
0.6
23.1
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.29
MCK's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
90% of the 10 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.33 vs. MCK: 0.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.04
MCK's Price-to-Median-PS-Value is ranked lower than
51% of the 45 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.01 vs. MCK: 1.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MCK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1 Max: 1.66
Current: 1.04
0.21
1.66
Price-to-Peter-Lynch-Fair-Value 0.40
MCK's Price-to-Peter-Lynch-Fair-Value is ranked higher than
94% of the 16 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.68 vs. MCK: 0.40 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MCK' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.34  Med: 1.05 Max: 2.11
Current: 0.4
0.34
2.11
Earnings Yield (Greenblatt) % 17.50
MCK's Earnings Yield (Greenblatt) % is ranked higher than
95% of the 56 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.37 vs. MCK: 17.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MCK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.5  Med: 8.8 Max: 20.6
Current: 17.5
4.5
20.6
Forward Rate of Return (Yacktman) % 25.53
MCK's Forward Rate of Return (Yacktman) % is ranked higher than
89% of the 35 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.37 vs. MCK: 25.53 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MCK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.6  Med: 20.6 Max: 85.1
Current: 25.53
1.6
85.1

More Statistics

Revenue (TTM) (Mil) $198,533.00
EPS (TTM) $ 22.74
Beta1.23
Short Percentage of Float1.55%
52-Week Range $114.53 - 197.91
Shares Outstanding (Mil)211.46

Analyst Estimate

Mar18 Mar19 Mar20
Revenue (Mil $) 205,882 212,462 224,054
EPS ($) 12.13 13.00 14.36
EPS without NRI ($) 12.13 13.00 14.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-5.47%
Dividends per Share ($) 1.14 1.15 1.23
» More Articles for MCK

Headlines

Articles On GuruFocus.com
What Is Fueling These Stocks' Bullish Movement? Jun 30 2017 
Insiders Roundup: SeaWorld, Kinder Morgan, Salesforce Jun 05 2017 
Richard Pzena Invests in 3 Health Care Companies May 09 2017 
What’s the Next Berkshire Hathaway Acquisition? May 02 2017 
Is Cardinal Health a Better Bargain Than Ever? Apr 18 2017 
The Threat and Risk of Rising Interest Rates: Separating Fact From Fiction Mar 24 2017 
Seth Klarman's Largest 4th-Quarter Buys Mar 16 2017 
Jerome Dodson Adds to 9 Positions in 4th Quarter Mar 01 2017 
Jana Partners' Largest 4th-Quarter Buys Mar 01 2017 
Searching For Value Feb 27 2017 

More From Other Websites
McKesson shareholders vote against exec pay structure Jul 26 2017
McKesson Executive Pay Plan Rejected After Teamsters Campaign Jul 26 2017
Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More Jul 26 2017
McKesson Announces Preliminary Voting Results From 2017 Annual Meeting of Stockholders Jul 26 2017
Teamsters, state treasurers call for changes at McKesson in wake of opioid crisis Jul 25 2017
Three US state treasurers seek change in McKesson exec pay policy Jul 25 2017
Teamsters to Protest McKesson's Shareholder Meeting Wednesday Jul 24 2017
Overdose Victim's Dad Rallies Teamsters in Fight With McKesson Jul 21 2017
McKesson (MCK) Q1 Earnings: Stock Likely to Beat Estimates? Jul 21 2017
High-Quality Stocks Gurus Are Buying Jul 19 2017
Congress is killing our productivity and depressing US GDP: NYSE trader Jul 19 2017
Today's weak dollar could lift stocks 2-3%: NYSE trader Jul 19 2017
McCormick mustard merger on National Hotdog Day Jul 19 2017
Stocks rally led by rebound in health care and crude oil Jul 19 2017
Cramer's lightning round: I'm all in on this financial wi... Jul 18 2017
Idaho news station apologizes for using photo of Black Lives Matter activist DeRay McKesson in... Jul 14 2017
McKesson (MCK) Poised on Improving Generic and Brand Market Jul 13 2017
Execution drug challenge survives, but Arkansas lacks doses Jul 12 2017
McKesson Corporation Fiscal 2018 First Quarter Conference Call Scheduled for July 27, 2017 Jul 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}